secwatch.observer — SEC 8-K summary
======================================

Issuer:     Eloxx Pharmaceuticals, Inc. (ELOX)
CIK:        0001035354
Form:       8-K
Filed at:   2022-07-15T23:59:59+00:00
Accession:  0001104659-22-080012
Event type: other_material
Sentiment:  neutral
Materiality: 0.40
Item codes: 4.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Eloxx Pharmaceuticals dismisses Deloitte, appoints Baker Tilly as auditor; no disagreements reported
--------------------------------------------------------------------------------

- Deloitte & Touche dismissed as independent auditor; Baker Tilly US, LLP engaged for FY 2022, effective July 13, 2022.
- No disagreements or reportable events between Eloxx and Deloitte during 2020, 2021, or through July 13, 2022.
- Deloitte's audit reports for FY 2020 and 2021 included a going concern doubt about the company's ability to continue.
- Deloitte confirmed agreement with the disclosures in a letter filed as Exhibit 16.1; no prior consultations with Baker Tilly.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1035354/000110465922080012/0001104659-22-080012-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1035354/000110465922080012/tm2221060d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-22-080012

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer